Body & veins / LANGEVIAX
Deoxycholic acid is an injectable medicine for a defined submental-fat indication, not a general license for fat-dissolving injections throughout the body. Assessment should first establish whether fullness comes from fat, skin or another medical cause.
Sources checked: 17 October 2026 · Independent clinical review of all pages is not complete.
A cell-disrupting drug, not a filler
The medicine disrupts cell membranes and destroys fat cells in the intended tissue; it is neither a filler nor a general skin-tightening treatment. Inflammation and swelling are part of the post-treatment course, but an unusual severity or duration needs review. Appropriate patient selection, genuine product and submental anatomical expertise are central to safety.
Section sources: ASPS · Injection lipolysis: mechanism, recovery and limits · Canadian product monograph · Deoxycholic acid, authorization 27 May 2025
Canadian indication and product checks
The Canadian indication is improvement in the appearance of moderate-to-severe fullness associated with submental fat in adults. Match the product and identifier against the official database and label. Authorization of one medicine does not validate every mixture or body site. US or other foreign approval is not, by itself, Canadian authorization.
Section sources: Health Canada Drug Product Database · Belkyra product entry · Health Canada · Deoxycholic acid submental indication
What may make the result unsuitable?
Marked loose skin, prominent neck-muscle bands or a different chin structure may make fat reduction an unsatisfactory solution. Disclose swallowing problems, neck surgery or injections, and local infection. A new lump or unexplained neck fullness needs diagnosis first. It should not move directly into a cosmetic package merely because the area resembles a double chin.
Section sources: Canadian product monograph · Deoxycholic acid, authorization 27 May 2025 · ASPS · Injection lipolysis: mechanism, recovery and limits
Treatment planning and expectations
Improvement is assessed gradually after inflammation subsides; early swelling can make the area look fuller. Repeat treatment may be required, with the plan determined by the clinician and the exact product label. Compare total costs, the threshold for stopping further treatment, observation, liposuction and appropriate surgical options before committing to a course.
Section sources: ASPS · Injection lipolysis: mechanism, recovery and limits · ASPS · Nonsurgical fat reduction compared with liposuction
Aftercare after injection
Follow the clinician’s written plan for swelling, discomfort and activity. A bland moisturizer on intact skin can help dryness, but a surface cream does not treat nerve injury or a deep mass. Do not improvise massage or cover symptoms with multiple anti-inflammatory medicines or cosmetics. Standardized photographs and the timing of symptoms can help the assessment.
Section sources: ASPS · Injection lipolysis: mechanism, recovery and limits · American Academy of Dermatology — Dermatologists' top tips for relieving dry skin
Take lip weakness and dysphagia seriously
An asymmetric smile or facial weakness can indicate marginal mandibular nerve injury and needs prompt clinician contact. New difficulty swallowing, severe pain, ulceration or an unusual color change also requires assessment. Breathing difficulty, choking or rapidly increasing throat swelling is an emergency; do not wait for a cream to work or for the expected swelling period to finish.
Section sources: Canadian product monograph · Deoxycholic acid, authorization 27 May 2025 · FDA · Deoxycholic acid safety update, 15 September 2026; US regulatory context
Persistent masses and treatment outside the area
A September 2026 US safety update highlights unresolved nodules or masses and serious harms after use outside the submental region. This is safety information, not a new Canadian authorization. A persistent mass, wound or discharge should not be dismissed as normal fat dissolving. Arrange an examination and reassess whether any further treatment is appropriate.
Section sources: FDA · Deoxycholic acid safety update, 15 September 2026; US regulatory context · FDA · Harm from unapproved fat-dissolving injections; US context
My consultation question sheet
Choose the questions to take with you. These selections are not sent to a clinic or saved to an account.
Printed sheet: the final procedure and product choice require consultation.
Frequently asked questions
Does this authorize injection into the abdomen or arms?
No. Submental evidence cannot be generalized throughout the body; the Canadian monograph does not recommend use outside that region.
Section sources: Canadian product monograph · Deoxycholic acid, authorization 27 May 2025
Should I wait if my smile becomes uneven?
Contact the clinician promptly for possible nerve weakness and an appropriate review plan.
Section sources: FDA · Deoxycholic acid safety update, 15 September 2026; US regulatory context
Is any vial marketed as fat dissolving acceptable?
No. The exact contents, route, authenticity and authorization must be checked.
Section sources: FDA · Harm from unapproved fat-dissolving injections; US context
Related guides to explore
Sources and context
Canadian sources take priority for regulatory context. FDA or other foreign information does not establish Canadian authorization for a product or use. A source-check date is distinct from publication date or independent clinical approval.
- ASPS · Injection lipolysis: mechanism, recovery and limitssociety · 2026-10-17
- Canadian product monograph · Deoxycholic acid, authorization 27 May 2025product-monograph · 2026-10-17
- Health Canada Drug Product Database · Belkyra product entryregulator · 2026-10-17
- Health Canada · Deoxycholic acid submental indicationregulator · 2026-10-17
- ASPS · Nonsurgical fat reduction compared with liposuctionsociety · 2026-10-17
- American Academy of Dermatology — Dermatologists' top tips for relieving dry skinUS specialist society guidance; general barrier-care principles, not a laser-product trial · 2026-10-17
- FDA · Deoxycholic acid safety update, 15 September 2026; US regulatory contextregulator · 2026-10-17
- FDA · Harm from unapproved fat-dissolving injections; US contextregulator · 2026-10-17
A next step that fits your question
Use Care to review related topics and prepare for a conversation. The product-label service can help organize ingredient information. The tools do not establish procedure candidacy or diagnose a complication.